Multiplexed assay kit advances single-cell selection

Sphere Bio has introduced the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay designed for its next-generation Cyto-Mine® Chroma platform. This innovative solution enhances single-cell selection by integrating antibody productivity and cell viability analysis in a single workflow, streamlining biotherapeutic development.

The Cyto-Mine Chroma platform uses fluorescence-based assays in picodroplets to select single cells based on secreted, surface, or intracellular markers. With the addition of multiplexing capabilities, researchers can now identify high-producing, viable clones more efficiently, reducing workflow times and improving selection accuracy. Early-stage screening helps eliminate non-viable or apoptotic clones, minimising false positives and ensuring only the most productive cells are chosen for downstream applications.

By simultaneously detecting secreted antibodies and assessing cell viability, this assay supports high-throughput screening in a fully automated workflow. Initial data suggest that approximately five percent of selected high-producing clones are apoptotic. Removing these early on reduces development risks and enhances the reliability of the selection process.

The Cyto-Cellect Human IgG Kappa and Viability Assay Kit, combined with Cyto-Mine Chroma, offers significant advantages, including advanced multiplexing for precise selection, streamlined workflows that reduce timelines from months to hours, and improved throughput at lower costs. Additionally, the system provides built-in monoclonality assurance, further strengthening its role in accelerating cell line development.

Sphere Bio's latest innovation marks an important step in its mission to provide transformative solutions that set new industry benchmarks. Dr Xin Liu, Senior Product Manager for Assays and Applications at Sphere Bio, emphasised that integrating viability assessment with antibody detection significantly enhances single-cell workflows, ensuring the selection of only the healthiest, most productive cells. Dr Maryam Ahmadi, Director of Science at Sphere Bio, highlighted that this launch is the first in a series of multiplex assays designed for the Chroma platform, bringing next-generation analytical capabilities to researchers and advancing biopharmaceutical discovery.

More information online